InnoCare Pharma prepares $300m Hong Kong IPO

Jonathan Breen

March 02, 2020 08:00 am

Pills_230px

Chinese biotechnology company InnoCare Pharma has won final approval for its Hong Kong IPO. The next step is marketing the deal, after delayed investor meetings in February.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs Health and Biotech Equity Hong Kong SAR Asia Greater China Morgan Stanley Northeast Asia Asia Pacific Emerging Markets SRI Goldman Sachs

JB

Jonathan Breen

Equities editor GlobalCapital Asia